Biochemical/immunochemical biomarkers of osteoarthritis: Utility for prediction of incident or progressive osteoarthritis

Rheumatic Disease Clinics of North America

Volumn 29, Issue 4, 2003, Pages 803-818

  Poole, A Robin ^a,b  

^a SHRINERS HOSPITAL FOR CHILDREN   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

BODY FLUID; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; HUMAN; INFLAMMATION; OSTEOARTHRITIS; PATIENT MONITORING; PRIORITY JOURNAL; REVIEW;

EID: 0142126184     PISSN: 0889857X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-857X(03)00056-5     Document Type: Review

References (66)

1. 2- as a measure of cartilage degradation [erratum appears in Magn Reson Med 1996;36:964]. Magn Reson Med 1996;36:665-73.
2. 2- as a measure of cartilage degradation [erratum appears in Magn Reson Med 1996;36:964]. Magn Reson Med 1996;36:665-73.
3. Poole AR. Cartilage in health and disease. In: Koopman W, editor. Arthritis and allied conditions. A textbook of rheumatology. 14th edition. Philadelphia: Lippincott, Williams & Wilkins; 2001. p. 226-84.
4. Poole AR, Howell DS. Etiopathogenesis of osteoarthritis. In: Moskowitz RV, Howell DS, Goldberg VM, Mankin HJ, editors. Osteoarthritis: diagnosis and management. 3rd edition. Baltimore: WB Saunders; 2001. p. 29-47.
5. Hanson DA, Weis MA, Bollen A-M, Maslan SL, Singer FR, Eyre DR. A specific immunoassay for monitoring human bone resorption: quantitation of type I collagen cross-linked N-telopeptides in urine. J Bone Min Res 1992;7:1251-8.
6. Cerejo R, Poole AR, Ionescu M, Lobanok T, Song J, Cahue S, et al. The association between cartilage activity measured in serum and progression of knee osteoarthritis in patients with and without evidence of generalized disease. Arthritis Rheum 2002;46: S144.
7. Garnero P, Rousseau J-C, Delmas PD. Molecular basis and clinical use of biochemical markers of bone, cartilage, and synovium in joint diseases. Arthritis Rheum 2000;43:953-68.
8. Lohmander LS, Poole AR. Defining and validating the clinical role of molecular markers in osteoarthritis. In: Brandt KD, Lohmander LS, Doherty M, editors. Osteoarthritis. 2nd edition. Oxford (UK): Oxford University Press; 2003. In press.
9. Otterness IG, Saltarelli MJ. Using molecular markers to monitor osteoarthritis. In: Tsokos GC, editor. Modern therapeutics in rheumatic diseases. Totawa (NJ): Humana Press; 2001. p. 215-36.
10. Poole AR. Skeletal and inflammation markers in aging and osteoarthritis. Implications for early diagnosis and monitoring of the effects of therapy. In: Hammerman D, editor. Osteoarthritis: public health implications for an aging population. Baltimore (MD): Johns Hopkins University Press; 1994. p. 187-214.
11. Poole AR. NIH white paper: biomarkers, the osteoarthritis initiative. National Institutes of Health, NIAMS News and Events. Available at: http://www.nih.gov/niams/news/org. Accessed 2000.
12. Billinghurst RC, Dahlberg L, Ionescu M, Reiner A, Bourne R, Rorabeck C, et al. Enhanced cleavage of type II collagen by collagenases in osteoarthritic articular cartilage. J Clin Invest 1997;99:1534-45.
13. Dahlberg L, Billinghurst C, Manner P, Ionescu M, Reiner A, Tanzer M, et al. Collagenase-mediated cleavage of type II collagen is selectively enhanced in osteoarthritis cartilage and can be arrested with a synthetic inhibitor which spares collagenase-1 (MMP-1). Arthritis Rheum 2000;43:673-82.
14. Squires G, Ionescu M, Okouneff S, Poole AR. The pathobiology of focal lesion development in aging human articular cartilage and molecular matrix changes characteristic of osteoarthritis. Arthritis Rheum 2003;48:1261-70.
15. Hollander AP, Heathfield TF, Webber C, Iwata Y, Rorabeck C, Bourne R, et al. Increased damage to type II collagen in osteoarthritic cartilage detected by a new immunoassay. J Clin Invest 1994;93:1722-32.
16. Wu W, Billinghurst RC, Pidoux I, Antoniou J, Zukor D, Tanzer M, et al. Sites of collagenase cleavage and denaturation of type II collagen in articular cartilage in ageing and osteoarthritis and their relationship to the distribution of the collagenases MMP-1 and MMP-13. Arthritis Rheum 2002;46:2087-94.
17. Downs JT, Lane CL, Nestor NB, McLellan TJ, Kelly MA, Karam GA, et al. Analysis of collagenase-cleavage of type II collagen using a neoepitope ELISA. J Immunol Methods 2001;247:25-34.
18. Kojima T, Mwale F, Yasuda T, Girard C, Poole AR, Laverty S. The comparative degradation of type IX and type II collagens and proteoglycan in articular cartilage in early experimental inflammatory arthritis. Arthritis Rheum 2001;44:120-7.
19. Song X-Y, Zeng L, Jin W, Thompson J, Mizel DE, Lei K-J, et al. Secretory leukocyte protease inhibitor suppresses the inflammation and joint damage of bacterial cell wall-induced arthritis. J Exp Med 1999;190:535-42.
20. Moskowitz RW, Holderbaum D, Atley LM, Eyre DR. Type II collagen c-telopeptide 2B4 epitope is a marker for cartilage degradation in familial osteoarthritis [abstract]. Arthritis Rheum 1998;41:S352.
21. Lohmander LS, Atley LM, Pietka TA, Eyre DR. The release of cross-linked peptides from type II collagen into joint fluid and serum is increased in osteoarthritis and after joint injury [abstract]. Trans Orthop Res Soc 2000;25:236.
22. Christgau S, Gamero P, Fledelius C, Moniz C, Ensign M, Gineyts E, et al. Collagen type II c-telopeptide tragments as an index of cartilage degradation. Bone 2001;29:209-15.
23. Gamero P, Piperno M, Gineyts E, Christgau S, Delmas PD, Vignon E. Cross sectional evaluation of biochemical markers of bone, cartilage and synovial tissue metabolism in patients with knee osteoarthritis: relations with disease activity and joint damage. Ann Rheum Dis 2001;60:619-26.
24. Aigner T, Zhu Y, Chonsky HH, Matsen III FA, Maloney WJ, Sandell LJ. Reexpression of type IIA procollagen by adult articular chondrocytes in osteoarthritic cartilage. Arthritis Rheum 1999;42:1443-50.
25. Eyre DR. Biochemical markers of bone turnover. In: Favus MJ, editor. Primer on the metabolic bone diseases and disorders of mineral metabolism. Philadelphia: Lippincott-Raven; 1996. p. 114-9.
26. Garnero P, Ayral X, Rousseau J-C, Christgau S, Sandell LJ, Dougados M, et al. Uncoupling of type II collagen synthesis and degradation predicts progression of joint damage in patients with knee osteoarthritis. Arthritis Rheum 2002;46:2613-24.
27. Nelson F, Dahlberg L, Laverty S, Reiner A, Pidoux I, Ionescu M, et al. Evidence for altered synthesis of type II collagen in patients with osteoarthritis. J Clin Invest 1998;102:2115-25.
28. Mort JS, Poole AR. Mediators of inflammation, tissue destruction and repair. D. Proteases and their inhibitors. In: Klippel JH, Crofford LJ, Sone JR, Wegard CM, editors. Primer on the rheumatic diseases. 12th edition. Atlanta (GA): Arthritis Foundation; 2001. p. 72-81.
29. Lark MW, Bayne EK, Flanagan J, Harper CF, Hoerrner LA, Hutchinson NI, et al. Aggrecan degradation in human cartilage. Evidence for both aggrecanase and matrix metalloproteinase activity in normal, osteoarthritic and rheumatoid joints. J Clin Invest 1997;100:93-106.
30. Carlson CS, Loeser RF, Johnstone B, Tulli HM, Dobson DB, Caterson B. Osteoarthritis in cynomolgus macaques II. Detection of modulated proteoglycan epitopes in cartilage and synovial fluid. J Orthop Res 1995;13:399-409.
31. Rizkalla G, Reiner A, Bogoch E, Poole AR. Studies of the articular cartilage proteoglycan aggrecan in health and osteoarthritis: evidence for molecular heterogeneity and extensive molecular changes in disease. J Clin Invest 1992;90:2268-77.
32. DiCesare PE, Carlson CS, Stolerman ES, Hauser N, Tulli H, Paulsson M. Increased degradation and altered tissue distribution of cartilage oligomeric protein in human rheumatoid and osteoarthritic cartilage. J Orthop Res 1996;14:946-55.
33. Recklies AD, Baillargeon L, White C. Regulation of cartilage oligomeric matrix protein synthesis in human synovial cells and articular chondrocytes. Arthritis Rheum 1998;41:997-1006.
34. Vilim V, Olejarova M, Machacek S, Gatterova J, Kraus VB, Pavelka K. Serum levels of cartilage oligomeric protein (COMP) correlate with radiographic progression of knee osteoarthritis. Osteoarthritis Cartilage 2002;10:707-13.
35. Robey PG. Bone matrix proteoglycans and glycoproteins. In: Bilezikian JD, Raisz LG, Rodan GA, editors. Principles of bone biology. New York: Academic Press; 1996. p. 155-65.
36. Sowers MF, Jannausch M, Stein E, Jamadar D, Hochberg M, Lachance L. C-reactive protein as a biomarker of emergent osteoarthritis. Osteoarthritis Cartilage 2002;10:595-601.
37. Vilim V, Vytasek R, Olejarova M, Machasek S, Gatterova J, Prochazka B, et al. Serum cartilage oligomeric matrix protein reflects the presence of clinically diagnosed synovitis in patients with knee osteoarthritis. Osteoarthritis Cartilage 2001;9:612-8.
38. Lohmander LS, Hoermer LA, Lark MW. Metalloproteinases-tissue inhibitor and proteoglycan fragments in knee synovial fluid in human osteoarthritis. Arthritis Rheum 1993;36:181-9.
39. Goldring MB. The role of the chondrocyte in osteoarthritis. Arthritis Rheum 2000;43:1916-26.
40. Melchiorri C, Meliconi R, Frizzerio L, Silvestri T, Pulsatelli L, Mazzetti I, et al. Enhanced and coordinated in vivo expression of inflammatory cytokines and nitric oxide synthase by chondrocytes from patients with osteoarthritis. Arthritis Rheum 1998;41:2165-74.
41. Sharif M, Elson CJ, Dieppe PA, Kirwan JR. Elevated C-reactive protein levels in osteoarthritis. Br J Rheumatol 1997;36:140-1.
42. Spector JD, Hart DJ, Nandra D, Doyle DV, Mackillop N, Gallimore JR, et al. Low level increases in serum C-reactive protein are present in early osteoarthritis of the knee and predict progressive disease. Arthritis Rheum 1997;40:723-7.
43. Poole AR, Ionescu M, Swan A, Dieppe PA. Changes in cartilage metabolism in arthritis are reflected by altered serum and synovial fluid levels of the cartilage proteoglycan aggrecan-implications for pathogenesis. J Clin Invest 1994;94:25-33.
44. Fife RS, Rachow JW, Ryan LM. Synovial fluid and plasma levels of cartilage matrix glycoprotein in arthritis. Calcif Tissue Int 1994;55:100-2.
45. Dragomir AD, Kraus VB, Renner JB, Luta G, Clark A, Vilim V, et al. Serum cartilage oligomeric matrix protein and clinical signs and symptoms of potential pre-radiographic hip and knee pathology. Osteoarthritis Carfilage 2002;10:687-91.
46. Poole AR, Witter J, Roberts N, Piccolo F, Brandt R, Pacquin J, et al. Inflammation and cartilage metabolism in rheumatoid arthritis. Studies of the blood markers hyaluronic acid, orosomucoid and keratan sulfate. Arthritis Rheum 1990;33:790-9.
47. Kojima T, Ishiguro N, Oguchi T, Billinghurst RC, Ionescu M, Poole AR. Serum levels of collagenase-cleaved type II collagen are related to ageing and disease activity in patients with rheumatoid arthritis. Arthritis Rheum 2001;44:S309.
48. Chu Q, Lopez M, Hayashi K, Ionescu M, Billinghurst RC, Johnson KA, et al. Elevation of a collagenase generated type II collagen neoepitope and a proteoglycan epitope in synovial fluid following induction of joint instability in the dog. Osteoarthritis Cartilage 2002;10:662-9.
49. Sowers M, Lachance L, Jamadar D, Hochberg MC, Hollis B, Crutchfield M, et al. The association of bone, mineral density and bone turnover markers with osteoarthritis of the hand and knee in pre and perimenopausal women. Arthritis Rheum 1999;42:483-9.
50. Lohmander LS, Saxne T, Heinegard D. Release of cartilage oligomeric matrix protein (COMP) into joint fluid after injury and in osteoarthrosis. Ann Rheum Dis 1994;53:8-13.
51. Lohmander LS, Yoshihara Y, Roos H, Kobayashi T, Yamada H, Shinmei M. Procollagen c-propeptide in joint fluid. Changes in concentrations with age, time after joint injury and osteoarthritis. J Rheumatol 1996;23:1765-9.
52. Lohmander LS, Ionescu M, Jugessur H, Poole AR. Changes in joint cartilage aggrecan metabolism after knee injury and in osteoarthritis. Arthritis Rheum 1999;42:534-44.
53. Clark AG, Jordan JM, Vilim V, Renner JB, Dragomir AD, Luta G, et al. Serum cartilage oligomeric matrix protein reflects osteoarthritis presence and severity: the Johnston County Osteoarthritis Project. Arthritis Rheum 1999;42:2356-64.
54. Otterness IG, Zimmerer RO, Swindell AC, Poole AR, Ionescu M, Weiner E. An analysis of 14 molecular markers for monitoring osteoarthritis: segregation of the markers into clusters and distinguishing osteoarthritis at baseline. Osteoarthritis Cartilage 2000;8:180-5.
55. Saxne T, Heinegard D. Cartilage oligomeric matrix protein: a novel marker of cartilage turnover detectable in synovial fluid and blood. Br J Rheum 1992;31:583-91.
56. Campion GV, Delmas PD, Dieppe PA. Serum and synovial osteocalcin (bone Gla protein) levels in joint disease. Br J Rheumatol 1989;28:393-8.
57. Zucker S, Lysik RM, Zarrabi MH, Greennwald RA, Gruber B, Tickle SP, et al. Elevated plasma stromelysin levels in arthritis. J Rheumatol 1994;21:2329-33.
58. Goldberg RL, Lenz ME, Huff J, Glickman P, Katz R, Thonar EJ-MA. Elevated plasma levels of hyaluronate in patients with osteoarthritis and rheumatoid arthritis. Arthritis Rheum 1991;34:799-807.
59. Hedin P-J, Weitoft T, Hedin H, Engström-Laurent A, Saxne T. Serum concentrations of hyaluronan and proteoglycan in joint disease. Lack of association. J Rheumatol 1991;18:1601-5.
60. Bathon JM, Martin RW, Fleischmann RM, Tessier JR, Schiff MH, Keystone EC, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000;343:1586-93.
61. Lipsky PE, van der Heijde DMFM, St. Clair EW, Furst DE, Breedveld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000;343:1594-602.
62. Sharif M, George E, Shepstone L, Knudson W, Thonar EJ-MA, Cushnaghan J, et al. Serum hyaluronic acid level as a predictor of disease progression in osteoarthritis of the knee. Arthritis Rheum 1995;38:760-7.
63. Petersson IF, Boegard T, Svensson B, Heinegård D, Saxne T. Changes in cartilage and bone metabolism identified by serum markers in early osteoarthritis of the knee joint. Br J Rheumatol 1998;37:46-50.
64. Sharif M, Saxne T, Shepstone L, Kirwan JR, Elson CS, Heinegard D, et al. Relationship between serum cartilage oligomeric matrix protein levels and disease progression in osteoarthritis of the knee joint. Br J Rheumatol 1995;34:306-10.
65. Conrozier T, Saxne T, Shan Sei Fan C, Mathieu P, Tran AM, Heinegård D, et al. Serum concentrations of cartilage oligomeric matrix protein and bone sialoprotein in hip osteoarthritis: a one year prospective study. Ann Rheum Dis 1998;57:527-32.
66. Chevalier X, Conrozier T, Gehrmann M, Claudepierre P, Mathieu P, Unger S, et al. Tissue inhibitor of metalloprotease-1 (TIMP-1) serum level may predict progression of hip osteoarthritis. Osteoarthritis Cartilage 2001;9:300-7.